Could Moderna Justify Its $129 Billion Valuation?

To say that Moderna's (NASDAQ: MRNA) COVID-19 vaccine has been a success would be a massive understatement, but there's no scenario where it justifies the company's $129 billion valuation all by itself. In this Fool Live video clip, recorded on Oct. 4, Fool.com contributor Matt Frankel discusses why Moderna's true value could lie in its future product pipeline. 

Continue reading

Source Fool.com